Max Bayer – Page 13 – Endpoints News

about the author

Max Bayer

Pharma Reporter

mbayer@endpointsnews.com

author articles

EMA's CHMP recommends 10 new drugs as Pierre Fabre overactive bladder med wins approval

11 months ago

Inside BARDA's multibillion-dollar effort to fund long-shot biotechs for Covid

11 months ago

Lykos takes another hit as ICER lays out 'insufficient' evidence for MDMA-based treatment

11 months ago

Updated: CDC expands RSV vaccine recommendations, namely for adults 75 and older

11 months ago

Moderna's updated RSV vaccine disappoints with only 50% efficacy

11 months ago

Lilly becomes the latest pharma to tap OpenAI for help, this time for antibiotic work

11 months ago

Korea-based Bridge Biotherapeutics closes Boston office

11 months ago

UK taps Pfizer over hometown GSK to supply RSV vaccine doses

11 months ago

Lykos’ pain is others’ gain as psychedelic biotechs take notes from adcomm vote

11 months ago

FDA to pharma companies: Using CRO Synapse's studies 'unacceptable'

11 months ago

Corrected: Emergent sells Baltimore facility for $30M

11 months ago

Intra-Cellular reports a depression win, setting up future competition with AbbVie's Vraylar

11 months ago

GSK readies Blenrep's commercial re-launch in the US, and a push in second line

11 months ago

Aerovate’s stock craters after PAH drug fails Phase 2 study

11 months ago

Updated: Takeda’s Ovid-licensed drug fails two Phase 3 epilepsy studies

11 months ago

Gilead's M&A appetite is for deals in the 'mid-single-digit billions,' CEO says

11 months ago

States join Oklahoma effort to convince Supreme Court to let them regulate PBMs

11 months ago

Lilly exec points to Medicare as more pay full list price for Zepbound than Mounjaro

11 months ago

BIO's new CEO takes a patriotic pivot to win back Congress, pushing industry to rethink China relationship

11 months ago

Paxlovid did not beat placebo in Stanford-led long Covid study

11 months ago

Oculis touts Phase 2 results in dry eye disease, but most data aren't statistically significant

11 months ago

Italian antitrust agency investigates Novartis, Biogen and others over Lucentis biosimilar

11 months ago

Aligos, Arbutus and others tout early hepatitis efficacy data at #EASL24

11 months ago

AbbVie gets first taste of Elahere potential with new mid-stage win

11 months ago

First page Previous page 10 11 121314 Next page Last page